Tegopen

(Cloxacillin)

PreclinicalSmall molecule

Bristol-Myers Squibb

Tegopen is one of 11 small molecule programs targeting Dialysis Patients. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Dialysis PatientsCompleted

Dialysis PatientsPreclinical

Completed

Competition

Competitive Landscape

14 competitors in Dialysis Patients

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Approved

2 2

Betadine

BBecton, Dickinson and Company

Approved

1 3

Sodium Valproate

AstraZeneca

Phase 3

2 4

Evrenzo

Astellas

Phase 2

2 5

KN060

SSuzhou Alphamab Co., Ltd.

Phase 2

1 6

Tirosint

IInstitut Jerome Lejeune

Preclinical

1 7

Deca-Durabolin

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Triferic

RRockwell Medical Technologies, Inc.

Preclinical

3 10

Tegopen

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Post-ApprovalRecruiting

MPA

NCT06726395

Clinical

Trials by Indication[1]

Staphylococcus Aureus Bacteremia2 trials

Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT03248063·315 enrolled

Staphylococcus Aureus Bacteremia Antibiotic Treatment Options

Completed·HHeinrich-Heine University, Duesseldorf·Phase 3·NCT01792804·215 enrolled

MPA1 trial

Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia

Recruiting·RRegion Skane·Phase 4·NCT06726395·420 enrolled

Bacteremia1 trial

Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.

Terminated·FFundación Pública Andaluza Progreso y Salud·Phase 3·NCT01875263·1 enrolled

Dialysis Patients1 trial

Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients

Completed·SShiraz University of Medical Sciences·N/A·NCT00885300·100 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

TEGOPEN

NDA NDA050192

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Cloxacillin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cloxacillin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cloxacillin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA050192). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bristol-Myers Squibb

Tegopen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Staphylococcus Aureus Bacteremia2 trials

MPA1 trial

Bacteremia1 trial

Dialysis Patients1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News